• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.

作者信息

Gertz Morie A, Landau Heather J, Weiss Brendan M

机构信息

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Am J Hematol. 2016 Dec;91(12):E506-E508. doi: 10.1002/ajh.24563. Epub 2016 Oct 21.

DOI:10.1002/ajh.24563
PMID:27648922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5132098/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5553/5132098/9e44ac62d252/AJH-91-E506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5553/5132098/9e44ac62d252/AJH-91-E506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5553/5132098/9e44ac62d252/AJH-91-E506-g001.jpg

相似文献

1
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.接受淀粉样蛋白定向单克隆抗体NEOD001治疗的AL淀粉样变性患者的器官反应
Am J Hematol. 2016 Dec;91(12):E506-E508. doi: 10.1002/ajh.24563. Epub 2016 Oct 21.
2
Beyond NEOD001 for systemic light-chain amyloidosis.超越用于系统性轻链淀粉样变性的NEOD001。
Blood. 2018 Nov 1;132(18):1992-1993. doi: 10.1182/blood-2018-07-865857. Epub 2018 Sep 21.
3
Novel Approaches for the Management of AL Amyloidosis.新型方法治疗轻链淀粉样变性病。
Curr Hematol Malig Rep. 2018 Jun;13(3):212-219. doi: 10.1007/s11899-018-0450-1.
4
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
5
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.淀粉样物质清除剂 birtamimab 的作用机制、药理学特性和临床应用，用于潜在治疗 AL 淀粉样变性。
Leuk Lymphoma. 2024 Aug;65(8):1068-1078. doi: 10.1080/10428194.2024.2337803. Epub 2024 Apr 11.
6
Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.单克隆抗体在治疗 AL 淀粉样变性中的作用：靶向浆细胞克隆和淀粉样沉积物。
Br J Haematol. 2020 Apr;189(2):228-238. doi: 10.1111/bjh.16436. Epub 2020 Feb 18.
7
Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.嵌合原纤维反应性单克隆抗体11-1F4治疗AL淀粉样变性患者的1a/b期研究的中期分析。
Amyloid. 2017 Mar;24(sup1):58-59. doi: 10.1080/13506129.2017.1292900.
8
Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.单克隆抗体疗法在系统性轻链淀粉样变性中的应用。
Hematol Oncol Clin North Am. 2020 Dec;34(6):1145-1159. doi: 10.1016/j.hoc.2020.08.005. Epub 2020 Oct 3.
9
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.NEOD001用于轻链淀粉样变性和持续性器官功能障碍患者的首次人体I/II期研究。
J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.
10
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.达雷妥尤单抗治疗2例晚期免疫球蛋白轻链淀粉样变性的安全性和有效性的首例报告。
Blood. 2016 Oct 13;128(15):1987-1989. doi: 10.1182/blood-2016-06-722496. Epub 2016 Aug 19.

引用本文的文献

1
Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain.将治疗性抗 Aβ 单克隆抗体重新设计为靶向淀粉样轻链。
Int J Mol Sci. 2024 Jan 27;25(3):1593. doi: 10.3390/ijms25031593.
2
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.心脏淀粉样变性的治疗现状与未来方向及预后
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
3
Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.淀粉样变性治疗模式的转变：从疾病修饰药物到抗淀粉样纤维治疗。

本文引用的文献

1
Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.超越浆细胞：免疫球蛋白轻链淀粉样变性的新兴治疗方法。
Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23.
2
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.NEOD001用于轻链淀粉样变性和持续性器官功能障碍患者的首次人体I/II期研究。
J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.
3
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.
Front Cardiovasc Med. 2022 Dec 20;9:1073503. doi: 10.3389/fcvm.2022.1073503. eCollection 2022.
4
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: State-of-the-Art Review.心脏病专家的AL淀粉样变性：认识、诊断及未来展望：最新综述
JACC CardioOncol. 2022 Nov 15;4(4):427-441. doi: 10.1016/j.jaccao.2022.08.009. eCollection 2022 Nov.
5
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.复发/难治性系统性轻链（AL）淀粉样变性的治疗选择：当前观点
J Blood Med. 2019 Oct 23;10:373-380. doi: 10.2147/JBM.S183857. eCollection 2019.
6
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).SAR228810：一种针对原纤维状淀粉样 β 肽的抗体，旨在降低淀粉样相关成像异常（ARIA）的风险。
Alzheimers Res Ther. 2018 Nov 28;10(1):117. doi: 10.1186/s13195-018-0447-y.
7
Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.双功能淀粉样蛋白反应肽促进抗体 11-1F4 与多种淀粉样蛋白类型结合，并增强治疗效果。
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10839-E10848. doi: 10.1073/pnas.1805515115. Epub 2018 Oct 30.
8
Novel Approaches for the Management of AL Amyloidosis.新型方法治疗轻链淀粉样变性病。
Curr Hematol Malig Rep. 2018 Jun;13(3):212-219. doi: 10.1007/s11899-018-0450-1.
9
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.2018 年免疫球蛋白轻链淀粉样变性诊断与治疗算法
Blood Cancer J. 2018 May 23;8(5):44. doi: 10.1038/s41408-018-0080-9.
10
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.快速血液学反应可改善极晚期（IIIb期）心脏免疫球蛋白轻链淀粉样变性患者的预后。
Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5.
AL 淀粉样变性中用于评估肾脏结局和化疗早期肾脏反应标志物的分期系统。
Blood. 2014 Oct 9;124(15):2325-32. doi: 10.1182/blood-2014-04-570010. Epub 2014 Aug 12.
4
Immunoglobulin light chain amyloidosis.免疫球蛋白轻链淀粉样变性
Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18.
5
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.系统性轻链淀粉样变性临床试验的实施和报告共识指南。
Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5.